Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

14.20 -0.04 (-0.25%)
Streaming Delayed Price Updated: 11:56 AM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Takeda Announces Completion of Acquisition of Own Shares
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
The  
Via Benzinga
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
From Takeda Pharmaceutical Company Limited
Via Business Wire
Monday Markets News
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID... 
Via Benzinga
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
From Takeda Pharmaceutical Company Limited
Via Business Wire
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
Via Benzinga
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four... 
Via Benzinga
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of... 
Via Benzinga
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Best Russell 2000 Stocks to Buy Before they Rebound
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices. 
Via InvestorPlace
Why Are Seagen Shares Sinking Today?
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues 
Via Benzinga
Take a Leap Into Novavax Stock After Vaccine Sales Start
Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch. 
Via InvestorPlace
A News Blizzard
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs. 
Via Talk Markets
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
From Takeda Pharmaceutical Company Limited
Via Business Wire
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Worldwide Adoption of Novavax Vaccines Makes It a Winner
Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels. 
Via InvestorPlace
Takeda Named Global Top Employer for Fifth Consecutive Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
More Serious Matters
Wall Street fell on new worries about inflation and a drop in retail sales levels. 
Via Talk Markets
Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
Denali Therapeutics is under pressure after the FDA put its study on hold. 
Via Investor's Business Daily
Interest Rate Hikes And Stocks
Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore. 
Via Talk Markets
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
From Takeda Pharmaceutical Company Limited
Via Business Wire
Post-Fed Thursday
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today. 
Via Talk Markets
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral... 
Via Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With... 
Via Benzinga
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.